Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis
The Canadian Skin Management in Oncology Group (CaSMO) developed an algorithm for the reduction of severity and management of acute RD, which follows previous publications from this group that addressed general oncology-treatment related cutaneous adverse events [AEs], prevention, and skin management.
Consumers of personal care products must be made aware of the potential pitfalls that arise from current labeling practices and regulations. For example, terms such as “hypoallergenic“, “sensitive skin“, and ...
The update covers: Tazarotene lotion, 0.045% - Arazlo™ (Bausch Health), Anifrolumab-fnia IV use - Saphnelo™ (AstraZeneca), Immune globulin intravenous (human) 10% - Octagam® 10% (Octapharma), Odevixibat capsule - Bylvay™ (Albireo Pharma) and other treatments
This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.
Moisturizers and Cleansers in the Management of Skin Conditions Caused by Personal Protective Equipment and Frequent Handwashing
Routine moisturization with non-irritating, pH-adjusted, ceramide-based products and gentle cleansing with a pH-adjusted cleanser can treat the unique dermatological challenges posed by COVID-19.
The update covers: Secukinumab for SC use - Cosentyx® (Novartis), Brincidofovir tablets and oral suspension - Tembexa® (Chimerix), Plasminogen, humantvmh - Ryplazim® (Liminal BioSciences), Halobetasol propionate lotion 0.01% w/w - Bryhali™ (Bausch Health), and Nomacopan for SC use (Akari Therapeutics).
Bimekizumab is a novel treatment for moderate-to-severe plaque psoriasis that has shown promising efficacy and safety in clinical trials. By simultaneously targeting two components of the IL-17 pathway, IL-17A and IL-17F, the biologic can downregulate proinflammatory signaling and rapidly improve patients’ skin.
Novel therapeutics are currently being explored for the treatment of Prurigo Nodularis. Nemolizumab and dupilumab both demonstrate promise in inhibiting specific central nervous system pathways responsible for transmission of the pruritic sensation.
The update covers: Axatilimab IV injection - SNDX-6352 (Syndax Pharmaceuticals), Binimetinib tablets + encorafenib capsules - Mektovi® + Braftovi® (Pfizer Canada), Encapsulated cell therapy for Fabry disease - SIG-007 (Sigilon Therapeutics) and Oritavancin IV injection - Kimyrsa™ (Melinta Therapeutics).
Certolizumab Pegol appears to offer a safe and effective psoriasis treatment for patients who are considering pregnancy, pregnant, or lactating based on its pharmacokinetics and available safety data.
HPV vaccines (Gardasil and Cervarix) may indeed have a therapeutic role in patients who suffer from dermatologic conditions that are associated with various strains of HPV.
The update covers: Cemiplimab-rwlc for IV injection - Libtayo® (Regeneron/Sanofi), HA-based dermal filler - Restylane® Defyne™ (Galderma), Tirbanibulin ointment 1% - Klisyri® (Almirall/Athenex), Anakinra for SC use - Kineret® (Swedish Orphan Biovitrum Sobi™), Immune modulatory vaccines for melanoma - IO102 and IO103 (IO Biotech).
Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients With Oncology Treatment-Related Skin Toxicities
The CaSMO (Canadian Skin Management in Oncology) algorithm focuses on general skincare measures to prevent or reduce the severity of cancer-treatment-related cutaneous toxicities.
Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.
Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis
Early clinical trial data indicate the increasing effectiveness and safety of efinaconazole 10% solution use beyond 12 months; application for up to 24 months appears to remain safe even for elderly patients.
This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.
Oral nicotinamide is an affordable over-the-counter supplement with demonstrated benefit in the treatment of a range of skin conditions, most notably AK and NMSC.
This update covers: Gene therapy for DEB (AGLE-102), Golimumab for IV use (Simponi® Aria™), Clascoterone 1% cream (Winlevi®), Triplet melanoma therapy (Tecentriq® + Cotellic® and Zelboraf®), Ustekinumab for SC use (Stelara®), Calcipotriene + betamethasone dipropionate cream (Wynzora®), Abametapir 0.74% lotion (Xeglyze™), Sonidegib capsules (Odomzo®) and Halobetasol propionate + tazarotene lotion (Duobrii™).
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, represent a new class of medication that have broad potential to treat dermatologic disease.
Dermatosis papulosa nigra is a benign skin lesion found most frequently on the face of patients with skin of color. This article compares treatment modalities for DPN.
This update covers: Guselkumab SC use (Tremfya®), Adalimumab-fkjp SC use (Hulio®), Collagenase clostridium histolyticum-aaes SC use (Qwo™), Protein replacement therapy for XLHED (ER-004), Pembrolizumab IV use (Keytruda®), Minocycline 1.5% foam (Zilxi™), Microbiome-based non-aqueous ointment (ATR-12), Dupilumab SC use (Dupixent®) and Selumetinib capsules (Koselugo™)
The addition of biologics that target IL-23p19 (Risankizumab) to our therapeutic armamentarium has succeeded in improving outcomes in patients with moderate-to-severe plaque psoriasis.
The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.
In two large randomized vehicle-controlled 12-week trials and in a 52-week open label study of moderate-to-severe acne at the face and trunk in subjects aged 9 years and older, trifarotene 50 μg/g cream demonstrated efficacy, safety, and cutaneous tolerability.
A number of research studies have documented the link between diet and skin aging. These results may be used to develop dietary recommendations that combat the forces of oxidation, inflammation, and glycation.
Given our current options for the treatment of Seborrheic Keratoses include only more invasive, non-topical therapies, Hydrogen Peroxide Topical Solution (40%) fills a void in our therapeutic repertoire as the first FDA-approved topical therapy for SKs.
This update covers Lebrikizumab SC injection (Dermira), Infliximab-axxq for IV injection (Avsola™, Amgen), Trifarotene cream 50 mcg/g (Aklief®, Galderma), Adalimumab-afzb for SC injection (Abrilada™, Pfizer), Lidocaine + tetracaine (7%/7%) local anesthetic cream (Pliaglis®, Crescita Therapeutics), Maralixibat oral solution (Mirum Pharmaceuticals), Cetirizine hydrochloride for IV injection (Quzyttir™, TerSera Therapeutics) and Minocycline foam 4% (Amzeeq™, Foamix)
Tildrakizumab is a promising therapeutic option for patients with moderate-to-severe chronic plaque psoriasis. The specificity of the drug in targeting the p19 subunit of IL-23 allows for the high efficacy and safety of long-term treatment as demonstrated in clinical trials.